Japan's Takeda Pharmaceutical has secured the largest ever syndicated bank loan in Asia to help pay for the cash portion of its $46bn acquisition of FTSE 100-listed Shire.
Just Group: Deutsche Bank initiates at hold with a target price of 170p.
Shire directors have agreed a takeover offer from Japan's Takeda Pharmaceutical in a mix of cash and shares that values the FTSE 100 biotech at roughly £46bn.
(WebFG News) - Playtech: Deutsche Bank reiterates buy with a target price of 1,300p.
(WebFG News) - Shire, which is in talks to be bought by Japan's Takeda Pharmaceutical, said it made a good start to 2018 as sales rose in the first quarter.
(WebFG News) - CityFibre: RBC Capital Markets downgrades to sector perform with a target price of 81p.
(WebFG News) - Shire directors said on Wednesday they would be willing to recommend the latest takeover proposal from Takeda Pharmaceutical that was pitched at roughly £49 per share, subject to certain terms.
(WebFG News) - Shire received a revised takeover proposal from Japan's Takeda Pharmaceutical on Tuesday, which the board said it was considering.
(WebFG News) - Following Weir's acquisition of US mining tools-maker ESCO, and the announcement of its intention to sell-off its Flow Control business, analysts at Credit Suisse approved of the course the deal had set the company on, in terms of revenue and market share expansion.
(WebFG News) - Esure: Peel Hunt upgrades to buy with a target price of 300p.
(WebFG News) - Shire received an improved takeover offer from Takeda Pharmaceutical on Friday, a day after turning down a £46.50 bid made up of shares and cash.
(WebFG News) - US pharma giant Allergan has pulled back from tabling a bid for UK-listed rival Shire just hours after first indicating its possible interest.
(WebFG News) - 1700:Close Stocks finished the session higher, led by Shire amid news that US rival Allergan had joined the fray for the rare-disease specialist, tabling a counter-offer to that from Japan's Takeda.
(WebFG News) - Shire has received and rejected a takeover approach from Japan's Takeda Pharmaceutical, but was later confirmed to be in talks with US giant Allergan.
Sage Group: JP Morgan downgrades to neutral with a target price of 670p.
Rentokil: Deutsche Bank downgrades to hold with a target price of 310p.
Shire, for whom the boss of Japanese drug maker Takeda is reportedly readying a £35bn bid, has agreed to sell its oncology business to Servier for $2.4bn in cash.
BHP Billiton: Societe Generale upgrades to buy with a target price of 1,600p.
1700:Close Stocks bounced back sharply on the back of gains for the Metals and Mining sector, as global trade tensions ebbed and metals' prices moved higher again.
1757:Close Far from a quiet sort of day suitable for an Easter egg hunt ahead of the long weekend, Thursday's session was choc-a-bloc. There was the tense conclusion of the soap opera-style GKN/Melrose will-they-won't-they drama, while a deluge of economic data and regulatory decisions to kept investors gripped down to the wire.